Almirall Goes All In On Generative AI
Dermatology-focused Almirall S.A. is partnering with Microsoft for generative artificial intelligence capabilities. It is the second generative AI-based collaboration announced by Almirall in several months.
You may also be interested in...
The Spanish drugmaker has licensed an IL-21 inhibitor which has been sitting on the shelf at Novo Nordisk and plans to start Phase II trials soon for as-yet undisclosed dermatological diseases.
The Spanish firm is all set to launch its atopic dermatitis drug in Germany later this month and is hopeful of a smooth reimbursement path across Europe.
Deal Snapshot: In Almirall’s first de novo artificial intelligence drug discovery and development collaboration, the company will pay up to $650m to work with Absci on two dermatology candidates.